Trial Profile
The Effects of Therapy With Teriparatide (Recombinant Parathyroid Hormone (1-34) on Vascular Compliance and Osteoprotegerin/RANKL
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Biomarker; Pharmacodynamics
- 26 Jan 2013 New trial record